Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own1.20% Shs Outstand218.94M Perf Week1.66%
Market Cap398.14M Forward P/E- EPS next Y-1.10 Insider Trans-0.98% Shs Float217.99M Perf Month-39.47%
Income-328.30M PEG- EPS next Q-0.33 Inst Own42.80% Short Float20.71% Perf Quarter-46.20%
Sales1.60M P/S248.84 EPS this Y-35.60% Inst Trans11.82% Short Ratio8.87 Perf Half Y-74.86%
Book/sh1.62 P/B1.14 EPS next Y33.10% ROA-63.50% Target Price5.67 Perf Year-73.14%
Cash/sh1.67 P/C1.10 EPS next 5Y- ROE-76.50% 52W Range1.60 - 10.33 Perf YTD-63.13%
Dividend- P/FCF- EPS past 5Y-7.60% ROI-72.60% 52W High-79.28% Beta0.91
Dividend %- Quick Ratio6.70 Sales past 5Y-45.00% Gross Margin- 52W Low33.76% ATR0.23
Employees317 Current Ratio6.70 Sales Q/Q-50.00% Oper. Margin- RSI (14)40.14 Volatility9.02% 8.69%
OptionableYes Debt/Eq0.05 EPS Q/Q-34.40% Profit Margin- Rel Volume12.02 Prev Close1.84
ShortableYes LT Debt/Eq0.05 EarningsMay 10 AMC Payout- Avg Volume5.09M Price2.14
Recom2.70 SMA20-15.46% SMA50-30.71% SMA200-60.91% Volume16,473,042 Change16.31%
May-11-22Downgrade Oppenheimer Outperform → Perform
Jan-21-22Upgrade BofA Securities Underperform → Neutral $8 → $10
Dec-29-21Resumed Jefferies Hold $8 → $6
Sep-10-21Downgrade BofA Securities Neutral → Underperform $9 → $8
Jun-24-21Initiated Jefferies Hold $9
Mar-23-21Initiated BofA Securities Neutral $13
Feb-12-21Initiated Oppenheimer Outperform $35
Nov-17-20Downgrade ROTH Capital Neutral → Sell
Nov-10-20Upgrade ROTH Capital Sell → Neutral $8
Sep-28-20Upgrade Maxim Group Hold → Buy $20
Sep-28-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jul-01-20Downgrade ROTH Capital Neutral → Sell $11
Jul-01-20Downgrade Maxim Group Buy → Hold
Jun-29-20Downgrade H.C. Wainwright Buy → Neutral
Jun-26-20Downgrade Stifel Buy → Hold $19 → $24
May-21-20Initiated The Benchmark Company Buy $28
Apr-30-20Downgrade ROTH Capital Buy → Neutral $13
Mar-13-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-13-20Downgrade Piper Sandler Overweight → Neutral
Dec-19-19Initiated ROTH Capital Buy $13
May-13-22 06:00AM  
May-11-22 10:10AM  
May-10-22 05:35PM  
May-09-22 08:25AM  
May-04-22 04:39PM  
May-03-22 08:25AM  
Apr-27-22 08:45AM  
Apr-26-22 08:00AM  
Mar-28-22 12:41PM  
Mar-24-22 03:00AM  
Mar-16-22 11:45AM  
Mar-08-22 08:00AM  
Mar-04-22 06:27PM  
Mar-02-22 04:12PM  
Mar-01-22 10:30PM  
Feb-17-22 08:12AM  
Feb-16-22 08:55AM  
Feb-15-22 08:00AM  
Feb-10-22 12:05PM  
Feb-02-22 12:43PM  
Jan-29-22 06:26AM  
Jan-25-22 10:00AM  
Jan-11-22 10:00AM  
Dec-30-21 03:49PM  
Dec-21-21 05:21PM  
Dec-19-21 08:33AM  
Dec-15-21 07:12PM  
Dec-14-21 08:00AM  
Dec-03-21 04:15PM  
Dec-02-21 06:30AM  
Nov-30-21 08:00AM  
Nov-26-21 06:04PM  
Nov-21-21 08:04AM  
Nov-17-21 06:54AM  
Nov-16-21 08:00AM  
Nov-15-21 08:00AM  
Nov-12-21 06:22PM  
Nov-10-21 12:30PM  
Nov-09-21 05:25PM  
Nov-05-21 08:00AM  
Nov-03-21 08:00AM  
Nov-02-21 03:02PM  
Nov-01-21 07:41AM  
Oct-27-21 08:00AM  
Oct-26-21 08:00AM  
Oct-21-21 08:00AM  
Oct-20-21 07:51AM  
Oct-13-21 05:51AM  
Oct-12-21 08:00AM  
Oct-11-21 08:00AM  
Oct-06-21 11:15AM  
Sep-29-21 08:00AM  
Sep-24-21 11:20AM  
Sep-22-21 08:00AM  
Sep-10-21 02:42PM  
Sep-08-21 06:06AM  
Sep-03-21 06:00AM  
Sep-01-21 08:00AM  
Aug-26-21 11:50AM  
Aug-25-21 09:12AM  
Aug-20-21 07:39AM  
Aug-17-21 03:08PM  
Aug-12-21 08:41AM  
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weiner David B.DirectorMay 16Sale1.959,00017,550892,625May 17 04:32 PM
Zoth Lota S.DirectorMay 16Sale1.983,6007,12839,416May 17 04:28 PM
BENITO SIMON XDirectorMar 16Option Exercise2.202,0004,40059,305Mar 17 04:03 PM
BENITO SIMON XDirectorMar 16Sale3.162,0006,32057,305Mar 17 04:03 PM
Weiner David B.DirectorMar 14Sale3.204,08313,066883,625Mar 14 04:41 PM
Weiner David B.DirectorMar 09Sale3.334,08313,596876,041Mar 09 04:05 PM
BENITO SIMON XDirectorJan 19Option Exercise2.202,0004,40059,305Jan 21 04:03 PM
BENITO SIMON XDirectorJan 19Sale4.272,0008,54057,305Jan 21 04:03 PM
Zoth Lota S.DirectorJan 05Sale5.019614,81525,016Jan 05 04:04 PM
Humeau LaurentChief Scientific OfficerAug 09Sale9.1510,31794,40168,587Aug 11 04:03 PM
KIES PETERCFOJun 09Option Exercise2.1613,75029,700164,538Jun 11 04:24 PM
Shea Jacqueline ElizabethChief Operating OfficerJun 09Sale10.0138,535385,73521,592Jun 11 04:26 PM
Humeau LaurentChief Scientific OfficerJun 09Sale9.0710,31893,58478,904Jun 11 04:25 PM
KIES PETERCFOJun 09Sale10.0133,750337,838130,788Jun 11 04:24 PM
KIES PETERCFOJun 03Sale8.0310,00080,300150,788Jun 04 04:08 PM